JP2021535152A5 - - Google Patents

Info

Publication number
JP2021535152A5
JP2021535152A5 JP2021510846A JP2021510846A JP2021535152A5 JP 2021535152 A5 JP2021535152 A5 JP 2021535152A5 JP 2021510846 A JP2021510846 A JP 2021510846A JP 2021510846 A JP2021510846 A JP 2021510846A JP 2021535152 A5 JP2021535152 A5 JP 2021535152A5
Authority
JP
Japan
Prior art keywords
disease
ripk2
composition according
pharmaceutical composition
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049071 external-priority patent/WO2020047414A1/en
Publication of JP2021535152A publication Critical patent/JP2021535152A/ja
Publication of JP2021535152A5 publication Critical patent/JP2021535152A5/ja
Pending legal-status Critical Current

Links

JP2021510846A 2018-08-31 2019-08-30 神経変性障害を処置するためのｒｉｐキナーゼの阻害法 Pending JP2021535152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725647P 2018-08-31 2018-08-31
US62/725,647 2018-08-31
PCT/US2019/049071 WO2020047414A1 (en) 2018-08-31 2019-08-30 Inhibition of rip kinases for treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
JP2021535152A JP2021535152A (ja) 2021-12-16
JP2021535152A5 true JP2021535152A5 (https=) 2022-09-02

Family

ID=69643080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510846A Pending JP2021535152A (ja) 2018-08-31 2019-08-30 神経変性障害を処置するためのｒｉｐキナーゼの阻害法

Country Status (8)

Country Link
US (2) US20210322427A1 (https=)
EP (1) EP3843773A4 (https=)
JP (1) JP2021535152A (https=)
KR (1) KR20210053303A (https=)
CN (1) CN112638405A (https=)
AU (1) AU2019328532A1 (https=)
CA (1) CA3109364A1 (https=)
WO (1) WO2020047414A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230357760A1 (en) * 2020-10-02 2023-11-09 The Trustees Of Dartmouth College Method and agent for treating/preventing neurodegenerative disease and associated neuroinflammation and for evaluating putative prophylactics/therapeutics for treating/preventing neurodegenerative disease and neuroinflammation
WO2023055733A1 (en) * 2021-09-30 2023-04-06 The Scripps Research Institute Compounds for reducing neuroinflammation
WO2023229445A1 (ko) * 2022-05-27 2023-11-30 주식회사 진큐어 신규 펩타이드 및 그의 용도
CN119997978A (zh) * 2022-11-09 2025-05-13 宁波康柏睿格医药科技有限公司 Rip2抑制剂联合免疫检查点抑制剂药物组合物及其应用
CN116617224A (zh) * 2023-05-04 2023-08-22 上海交通大学医学院附属瑞金医院 OPN和p38 MAPK信号通路靶向调控剂在制备神经退行性疾病药物中的应用
CN118304388B (zh) * 2024-04-03 2025-02-11 南通大学 Tak1在制备治疗周围神经损伤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130005726A1 (en) * 2010-03-08 2013-01-03 Derek Abbott Compositions and methods for treating inflammatory disorders
US20120046329A1 (en) * 2010-08-10 2012-02-23 Sanford-Burnham Medical Research Institute Modulators of nod1 and nod2 signaling, methods of identifying modulators of nod1 and nod2 signaling, and uses thereof
EP2620156B1 (en) * 2010-08-23 2019-03-27 Kang Stem Biotech Co., Ltd. Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof
EA029234B1 (ru) * 2011-07-06 2018-02-28 Сюкехусет Сёрланнет Хф Нацеленная на egfr терапия
US20150292012A1 (en) * 2012-10-26 2015-10-15 Case Western Reserve University Biomarkers for nod2 and/or rip2 activity related application
EP3092496B1 (en) * 2014-01-11 2020-05-06 The J. David Gladstone Institutes In vitro assays for inhibition of microglial activation
EP3233840B1 (en) * 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
KR20160129609A (ko) * 2015-04-30 2016-11-09 삼성전자주식회사 Ｂｒａｆ 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2021535152A5 (https=)
Nguyen et al. Nanotechnology-based drug delivery for central nervous system disorders
US11221329B2 (en) Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
EA201991078A1 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
NZ601547A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2009017453A1 (en) New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
MX2021000904A (es) Forma de dosificacion farmaceutica administrable por via oral con liberacion modificada.
US20210008039A1 (en) Promoting sleep using at1 receptor blockers
Ortega et al. Indications of dexmedetomidine in the current sedoanalgesia trends in the critical patient
JP2015508824A5 (https=)
JP2019530711A5 (https=)
JP2025508308A5 (https=)
JP7369693B2 (ja) てんかん性の疾患、障害、または病態の処置に使用するためのプロベネシド
JP2012502105A5 (https=)
JP2022514799A5 (https=)
WO2005105089A1 (ja) 精神神経疾患の治療薬
JP6587299B2 (ja) 抗てんかん薬
TWI474825B (zh) 治療神經損傷之醫藥套組
JP6734469B2 (ja) ヒスタミン−３受容体インバースアゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種組合せ
JP6734470B2 (ja) ヒスタミン−３受容体インバースアゴニストとアセチルコリンエステラーゼ阻害剤との組合せ
Di Fabio et al. Hydroxyzine hydrochloride in familial restless legs syndrome
Chue Gabapentin treatment for premature ejaculation
Park et al. Insomnia in Parkinson’s disease
WO2025006917A1 (en) Uses of iron chelators for treating stuttering
TW202535409A (zh) 用於治療神經退化性病症之組合物及方法